

Medical Necessity

WA.PHAR.154

Effective Date: 2/1/2026

To see the list of the current publication of the Coordinated Care of Washington, Inc. Preferred Drug List (PDL), please visit:
https://www.coordinatedcarehealth.com/content/dam/centene/centene-pharmacy/pdl/FORMULARY-CoordinatedCare_Washington.pdf

Medical necessity

Medical Necessity

This is a general pharmacy program policy used to determine medical necessity for drugs without a drug specific policy.

For covered drugs and conditions, in cases where the criteria are not met, the clinical reviewer may use their professional judgement to determine there is a medically necessary need and approve on a case-by-case basis. The clinical reviewer may choose to use the reauthorization criteria when a patient has been previously established on therapy and is new to Apple Health.

Clinical policy:

Clinical Criteria

Medical Necessity	<p>Drugs may be considered medically necessary when all the following documented criteria is met:</p> <ol style="list-style-type: none">1. For patients 21 years of age or older, the requested agent is not:<ol style="list-style-type: none">a. Excluded from coverage; ORb. Being used to treat a medical condition/disease state that is excluded from coverage; AND2. The following are met:<ol style="list-style-type: none">a. Prescribed in accordance with FDA labeling; ORb. Prescribed for a condition supported in compendia, classified as follows:<ol style="list-style-type: none">i. Strength of evidence*: Category A or B; ANDii. Strength of recommendation*: Class 1 or 2a; ANDc. Is prescribed within the FDA labeling or is compendia supported for age, dose and dosing frequency; AND3. Patient meets one of the following:<ol style="list-style-type: none">a. Documentation of a history of failure, contraindication, or intolerance to all preferred first-line therapies as recommended in North American or World Health Organization (WHO) evidence based practice guidelines (other guidelines may be used on a case-by-case basis), FDA-approved or compendia supported therapeutic alternatives (with or without PA), for the treatment of patient's condition; OR
-------------------	---

	<p>b. Requested agent is refill protected under RCW 69.41.190 (1)(a) and all the following are met:</p> <ul style="list-style-type: none"> i. Patient received the same active ingredient as the requested agent within the last 30 days; AND ii. Patient is not continuing therapy based off being established on samples, manufacturer coupons, or otherwise; AND iii. Drug is in a refill protected AHPDL drug class (see Table 1). <p>If ALL criteria are met, the request may be authorized up to 12 months.</p>
Criteria (Reauthorization)	

References

*Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at:
<https://www.micromedexsolutions.com/>

Table 1: Refill Protected AHPDL Drug Classes

All AHPDL drug classes that fall within the therapeutic classes listed below apply

Refill Protected AHPDL Drug Classes
ADHD / ANTI-NARCOLEPSY : NON-STIMULANTS
ADHD / ANTI-NARCOLEPSY : STIMULANTS
ANTICONVULSANTS
ANTIDEPRESSANTS
ANTIPSYCHOTICS / ANTIMANIC AGENTS
HIV
IMMUNOSUPPRESSIVE AGENTS TO PREVENT ORGAN REJECTION POST TRANSPLANT
ONCOLOGY AGENTS

History

Approved Date	Effective Date	Version	Action and Summary of Changes
10/21/2025	2/1/2026	NC 0002-1	New non-clinical policy